Bio NC
Filter News
Found 17,615 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
11/30/2023
G1 Therapeutics, Inc. announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer from the Company’s Phase 2 trial will be presented in a poster session during the upcoming 2023 San Antonio Breast Cancer Symposium, held December 5th through 9th in San Antonio, TX.
-
Precision BioSciences to Present at Hep-DART 2023
11/30/2023
Precision BioSciences, Inc. today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
11/29/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
-
IQVIA Digital Enablement Named PM360 Trailblazer 2023 Supplier/Vendor of the Year
11/29/2023
IQVIA™ today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category.
-
ArrivoBio Raises $45M in Series B Financing to Advance Pipeline
11/29/2023
Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $100M.
-
Ribometrix to Present Additional Preclinical Data for eIF4E Program at the San Antonio Breast Cancer Symposium
11/29/2023
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present preclinical data showing anti-tumor benefit of eIF4E inhibition in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium, held December 5-9, 2023, in San Antonio, TX.
-
BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
11/29/2023
BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.
-
Belhaven Biopharma Achieves Significant Milestones in Advancing Nasdepi - a Revolutionary Nasal Dry Powder Epinephrine Product
11/28/2023
Belhaven Biopharma proudly announces new Board of Director appointments and the initiation of a first in human clinical trial that positions the company as a novel alternative in the $2.5 billion U.S. epinephrine market.
-
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
11/28/2023
Precision BioSciences, Inc. today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee.
-
EmergeOrtho-Triangle Region Welcomes Prominent Anesthesiologist and Pain Management Physician Dr. Robert Baranello
11/28/2023
EmergeOrtho is thrilled to announce the newest addition to its esteemed team in the Triangle Region, Dr. Robert Baranello, a double board-certified anesthesiologist and a pain management specialist.
-
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
11/27/2023
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that the U.S. FDA (U.S. Food and Drug Administration) has granted five years' market exclusivity for Talicia.
-
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/24/2023
Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock.
-
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
11/24/2023
Humacyte, Inc. today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will present at the Piper Sandler 35th Annual Healthcare Conference, in New York, NY on November 30, 2023.
-
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
Milestone Pharmaceuticals Inc. announced that members of its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023, at 10:30 a.m. Eastern Time.
-
BioCryst to Present at Upcoming Investor Conferences - November 21, 2023
11/21/2023
BioCryst Pharmaceuticals, Inc. announced that the company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th in Miami at 9:35 a.m. ET and the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29th in New York at 12:30 p.m. ET.
-
BioCryst Launches ORLADEYO® (berotralstat) in Spain
11/21/2023
BioCryst Pharmaceuticals, Inc. announced that the Spanish Ministry for Health has granted marketing authorization for oral, once-daily ORLADEYO® for the routine prevention of recurrent hereditary angioedema attacks in HAE patients 12 years and older.
-
IQVIA CFO Ron Bruehlman to Speak at Evercore HealthCONx Conference on November 29, 2023
11/21/2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on Wednesday, November 29, 2023 at 10:50 a.m. ET.
-
Global Leader Advancing Cancer Treatment, Dr. Christel Smith, Joins Fuse Oncology as Chief Technology Officer
11/20/2023
Fuse Oncology, a trailblazing leader in radiation oncology software solutions, is pleased to announce the appointment of Dr. Christel Smith as its new Chief Technology Officer.
-
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
11/20/2023
Daré Bioscience, Inc. and Premier Research International, LLC announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclusive basis contract research organization services within the United States to support the clinical development of Daré’s reproductive health portfolio.